ClinicalTrials.gg
Status unknownNCT05321732Updated Apr 11, 2022

The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults

A Phase 1 interventional study of DWP16001 and DWP202010 in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This study aims to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety of co-administration of DWP16001 2 mg and DWC202010 (DWC202010 37.5 mg) in healthy adults compared to the case of administration alone.

Read the detailed description

The study design is a randomized, open-label, multiple-dose, crossover clinical trial. The patients were randomly assigned to each group. Primary endpoint was Cmax,ss and AUCtau,ss of DWP16001 and DWC202010. Secondary endpoints were Cmax,ss, Tmax,ss, t1/2, CLss/F, fluctuation of DWP16001 and DWC202010, and Cmax,ss, Cmin,ss, AUCtau,ss, Tmax,ss, and metabolic ratio of DWP16001 metabolites(M1).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Intervention: DWP16001 A mg

    Drug: DWP16001

  • Experimental
    Intervention: DWC202010 B mg

    Drug: DWP202010

  • Experimental
    Intervention: DWP16001 A mg + DWC202010 B mg

    Drug: DWP16001 · Drug: DWP202010

Interventions

  • DWP16001 A mg

  • DrugDWP202010

    DWP202010 B mg

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax,ss) of DWP16001

    Time frame: Before IP administration of Day 1, Day 5, and Day 6

  2. Area under the plasma concentration versus time curve (AUCtau,ss) of DWP16001

    Time frame: Before IP administration of Day 1, Day 5, and Day 6

  3. Peak Plasma Concentration (Cmax,ss) of DWC202010

    Time frame: Before IP administration and post-dose up to 24 hours

  4. Area under the plasma concentration versus time curve (AUCtau,ss) of DWC202010

    Time frame: Before IP administration and post-dose up to 24 hours

07

Study locations

1 site
  • Yonsei University Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Aug 2022, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2022
First posted
Apr 11, 2022
StartActual
Dec 10, 2021
Primary completionEst.
Aug 2022
CompletionEst.
Aug 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05321732
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Dec 10, 2021
Primary completion
Aug 2022 (estimated)
Completion
Aug 2022 (estimated)
Last update
Apr 11, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion